Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.36 |
| ▸ | SAT1 | P21673 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18402615 | 0.80 | GNAO1 (0.54) | GNAO1GNAI3GNAI1ITGB3ITGA2B | |
| SCHEMBL12844968 | 0.77 | GNAO1 (0.46) | GNAO1GNAI3GNAI1ITGB3ITGA2B | |
| SCHEMBL12308362 | 0.74 | GNAO1 (0.39) | MAPTGNAO1GNAI3GNAI1ITGB3 | |
| SCHEMBL5807689 | 0.73 | GNAO1 (0.47) | MAPTGNAO1GNAI3GNAI1ITGB3 | |
| SCHEMBL13575302 | 0.71 | GNAI3 (0.34) | GNAO1GNAI3GNAI1SAT1 | |
| SCHEMBL12524730 | 0.71 | GNAO1 (0.45) | GNAO1GNAI3GNAI1SAT1HRH3 | |
| SCHEMBL5280135 | 0.71 | ITGB3 (0.37) | MAPTGNAO1GNAI3GNAI1ITGB3 | |
| SCHEMBL27286241 | 0.71 | CYP2C19 (0.45) | SAT1 | |
| SCHEMBL7109086 | 0.69 | TSHR (0.52) | — | |
| SCHEMBL11507752 | 0.69 | CYP2C19 (0.52) | SAT1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070383-A1 | POLYMERIC NANO-CARRIERS WITH A LINEAR DUAL RESPONSE MECHANISM AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070383-A1 | POLYMERIC NANO-CARRIERS WITH A LINEAR DUAL RESPONSE MECHANISM AND USES THEREOF | ROS1, CYBB, NOX4 | MAPT 1414/4885GNAO1 2446/4885GNAI3 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.